

November 21, 2014



# Time Magazine Names The Aethlon Hemopurifier® One of the 25 Best Inventions of 2014

SAN DIEGO, Nov. 21, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® has been named one of the 25 best inventions of 2014 by Time Magazine. The article can be found on-line at the following link: <http://time.com/3594971/the-25-best-inventions-of-2014>



The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. To date, the device has been utilized in the treatment of Ebola, HIV and Hepatitis C virus. Time previously reported on the successful use of Hemopurifier® therapy in an Ebola patient with multiple organ failure. The article can be found on-line at the following link: <http://time.com/3586271/ebola-treatment-dialysis-blood>

## About Aethlon Medical, Inc.

Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit <http://www.aethlonmedical.com/> and connect with the Company on

[Twitter](#), [LinkedIn](#), [Facebook](#) and [Google+](#).

*Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

Contacts:

Leah-Michelle Nebbia (for interviews requests)

Golin

202-585-2651

[lnebbia@golin.com](mailto:lnebbia@golin.com)

James A. Joyce

Chairman and CEO

(Office) 858.459.7800 x301

(Cell) 619-368-2000

[jj@aethlonmedical.com](mailto:jj@aethlonmedical.com)

Jim Frakes

Chief Financial Officer

858.459.7800 x300

[jfrakes@aethlonmedical.com](mailto:jfrakes@aethlonmedical.com)

Logo - <https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b>

SOURCE Aethlon Medical, Inc.